Why Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?

Group 1 - Adial Pharmaceuticals' stock is experiencing a significant increase following positive peer-reviewed results for its Alcohol Use Disorder (AUD) treatment, AD04 [1] - The peer review published in the European Journal of Internal Medicine emphasizes the treatment's efficacy and safety, particularly for patients with a specific genetic background [1] - CEO Cary Claiborne highlighted the potential of AD04 to enable precision treatments for AUD, aiming to manage alcohol consumption and reduce liver damage [1] Group 2 - Heavy trading activity was noted, with over 75 million shares of ADIL stock changing hands, significantly surpassing the average daily trading volume of approximately 4 million shares [2] - As of Wednesday morning, ADIL stock rose by 59.3%, recovering its year-to-date losses [2]